Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Anacor Pharmaceuticals, Inc. (ANAC)
|
Add to portfolio |
|
|
|
| Price: |
$9.78
| | Metrics |
| OS: |
45.4
|
M
| |
-144
|
% ROE
|
| Market cap: |
$444
|
M
| |
|
|
|
Net cash:
|
$73.4
|
M
| |
$1.62
|
per share
|
|
EV:
|
$370
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($58.8)
|
M
| |
|
|
|
EBIT
|
($59.5)
|
M
| |
|
|
| EPS |
($1.46)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-15 | Dec-31-14 | Dec-31-13 | Dec-31-12 | Dec-31-11 | Dec-31-10 | Dec-31-09 | Dec-31-08 |
| Revenues | 82.4 | 20.7 | 17.2 | 0.0 | 20.3 | 27.8 | 18.6 | 25.1 |
| Revenue growth | 298.1% | 20.1% | | -100.0% | -27.0% | 49.2% | -25.7% | 17.8% |
| Cost of goods sold | 4.0 | 0.8 | 150.6 | -10.7 | 0.0 | 0.0 | 0.0 | 10.2 |
| Gross profit | 78.3 | 19.9 | -133.4 | 10.7 | 20.3 | 27.8 | 18.6 | 14.9 |
| Gross margin | 95.1% | 96.1% | -774.0% | | 100.0% | 100.0% | 100.0% | 59.4% |
| Selling, general and administrative | 60.9 | 31.4 | 20.7 | 11.6 | | | | |
| Research and development | 73.9 | 72.5 | 46.6 | | 56.1 | 29.9 | 34.1 | |
| General and administrative | | | | | 10.6 | 7.5 | 7.1 | 10.2 |
| EBIT | -56.4 | -90.8 | -50.0 | -53.2 | -46.3 | -9.5 | -22.5 | -21.3 |
| EBIT margin | -68.5% | -438.9% | -290.1% | | -228.2% | -34.1% | -120.7% | -84.9% |
| Pre-tax income | -61.2 | -97.4 | 86.5 | -56.1 | -47.9 | 0.0 | -24.9 | -21.7 |
| Income taxes | 0.0 | -10.3 | 1.7 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 10.5% | 2.0% | 0.0% | 0.0% | | 0.1% | 0.2% |
| Net income | -61.2 | -87.1 | 84.8 | -56.1 | -47.9 | -10.1 | -24.8 | -21.6 |
| Net margin | -74.4% | -421.3% | 492.0% | | -236.1% | -36.1% | -133.2% | -86.2% |
| |
| Diluted EPS | ($1.39) | ($2.06) | $2.10 | ($1.76) | ($1.71) | ($2.71) | ($17.55) | ($15.39) |
| Shares outstanding (diluted) | 43.9 | 42.2 | 40.3 | 31.9 | 28.1 | 3.7 | 1.4 | 1.4 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|